Abstract 77P
Background
Radical lymph nodes (LNs) dissection is the cornerstone of gastric cancer (GC) surgical treatment. Indocyanine green (ICG) fluorescence imaging-guided lymphadenectomy has been proven to be effective in increasing the number of LNs retrieved in laparoscopic gastrectomy (LG) for GC. However, the long-term oncological efficacy of ICG fluorescence imaging in LG remains uncertain. This randomized clinical trial was conducted to evaluate the long-term oncological efficacy of ICG imaging-guided laparoscopic lymphadenectomy for GC.
Methods
The study was an open-label, randomized clinical trial conducted at a tertiary referral teaching hospital in China. A total of 266 eligible patients with potentially resectable GC (cT1-4a, N0/+, M0) without bulky nodes or distant metastases were enrolled from November 2018 to July 2019. Patients were randomly (1:1 ratio) assigned to the ICG group or the non-ICG group.
Results
Among 266 patients, 258 (97.0%; mean age, 58.9 years; 85 [32.9%] women) completed the study. The mean (SD) total number of LNs retrieved in the ICG group was 50.5 (15.9), which was significantly more than that of the non-ICG group (42.0 [10.3], P < 0.001). The 3-year disease-free survival (DFS) of the ICG group and the non-ICG group were 81.4% and 68.2%, respectively, with an absolute risk difference of 13.2% (Log-rank P = 0.012). The 3-year overall survival (OS) in the ICG group was 86.0%, which was significantly higher than that in the non-ICG group (73.6%; Log-rank P = 0.015). Cox multivariate analysis showed ICG was the independent protective factor for both OS and DFS (OS: HR=0.49, 95%CI: 0.27-0.91; P = 0.023; DFS: HR=0.51, 95%CI: 0.30-0.87; P = 0.014).There were differences in overall recurrence patterns between the ICG and non-ICG groups within 3 years after surgery (17.9% vs. 31.0%, P = 0.014).
Conclusions
For patients with resectable GC, ICG fluorescence imaging-guided laparoscopic lymphadenectomy showed better long-term oncological efficacy than conventional LN dissection, especially in patients undergoing total gastrectomy. These findings provided encouraging evidence for the ongoing, randomized, phase 3, CLASS-11 study (NCT03875235).
Clinical trial identification
NCT03875235.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
79P - Outcomes by baseline liver function in patients with unresectable hepatocellular carcinoma treated with tremelimumab and durvalumab in the phase III HIMALAYA study
Presenter: Arndt Vogel
Session: Poster viewing 02
82P - A randomized controlled, open-label, adaptive phase III clinical trial to evaluate safety and efficacy of EndoTAG-1 plus gemcitabine versus gemcitabine alone in patients with measurable locally advanced and/or metastatic adenocarcinoma of the pancreas after FOLFIRINOX
Presenter: Muh-Hwan Su
Session: Poster viewing 02
83P - Impact of viral aetiology in the phase III HIMALAYA study of tremelimumab (T) plus durvalumab (D) in unresectable hepatocellular carcinoma (uHCC)
Presenter: Stephen Chan
Session: Poster viewing 02
84P - Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: A large real life worldwide population
Presenter: Margherita Rimini
Session: Poster viewing 02
86P - Outcomes by primary tumour location in patients with advanced biliary tract cancer treated with durvalumab or placebo plus gemcitabine and cisplatin in the phase III TOPAZ-1 study
Presenter: Aiwu Ruth He
Session: Poster viewing 02
87P - Socio-demographic disparities in esophageal cancer: A SEER analysis
Presenter: Beas Siromoni
Session: Poster viewing 02
88P - Sintilimab plus anlotinib as second-line therapy for metastatic or recurrent gallbladder carcinoma (GBC): A single-arm, phase II study
Presenter: Qingbao Cheng
Session: Poster viewing 02